The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Darolutamide for patients with androgen receptor positive salivary gland cancers (DISCOVARY): The results of phase 2 study of darolutamide monotherapy.
 
Susumu Okano
Speakers' Bureau - Bristol-Myers Squibb Japan; Meiji Seika Kaisha; Merck Serono; MSD; Ono Pharmaceutical
 
Makoto Tahara
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Lilly; Merck Serono; MSD; Ono Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Genmab; Janssen; Lilly; MSD; Nanobiotix; Nektar; Ono Pharmaceutical; Pfizer; Rakuten Medical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Rakuten Medical (Inst)
 
Yoshinori Imamura
Speakers' Bureau - Daiichi Sankyo/UCB Japan; MSD
 
Hideoki Uryu
No Relationships to Disclose
 
Tomoyuki Otsuka
No Relationships to Disclose
 
Akira Ohkoshi
No Relationships to Disclose
 
Daisuke Sano
Consulting or Advisory Role - Merck Serono
Speakers' Bureau - Merck Serono; MSD
 
Kiyoaki Tsukahara
No Relationships to Disclose
 
Kazuchika Ono
No Relationships to Disclose
 
Toyoyuki Hanazawa
No Relationships to Disclose
 
Satoshi Kano
No Relationships to Disclose
 
Naoki Nishio
No Relationships to Disclose
 
Masato Nagaoka
No Relationships to Disclose
 
Naomi Kiyota
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Eisai; Lilly Japan; Merck Serono; MSD; Ono Pharmaceutical
Consulting or Advisory Role - Adlai Nortye; Ono Pharmaceutical; Shift Zero
Research Funding - Adlai Nortye (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Ono Pharmaceutical (Inst); Rakuten Medical (Inst)